Changing the Autoimmune Disease Playbook with RNA-Engineered CAR T Cells

Autoimmune diseases like myasthenia gravis have long forced patients to trade daily function for chronic immunosuppression, but Cartesian Therapeutics is betting that its experimental RNA‑engineered CAR T cells can rewrite that equation. The company’s lead experimental therapy, Descartes‑08, is designed to deliver deep, durable remissions through a short course of outpatient infusions that selectively eliminate the plasma cells driving disease, while sidestepping the toxicity and logistical hurdles of conventional DNA‑based CAR T therapies. We spoke to Carsten Brunn, CEO of Cartesian Therapeutics, about how the company’s RNA‑engineered CAR T cells target the root cause of autoimmune diseases, data from its phase 2 study in myasthenia gravis, and the potential to expand the approach into myositis and other rare autoimmune indications.

You can listen to Changing the Autoimmune Disease Playbook with RNA-Engineered CAR T Cells online on Radio and Podcast. Open the player on this page to stream the available audio.

Changing the Autoimmune Disease Playbook with RNA-Engineered CAR T Cells is an episode from RARECast by RARECast.

This episode is 00:22:11 long.

This episode was published on Feb 12, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from RARECast when more episodes are available from the podcast feed.